Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 9/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 9/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 9/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 9/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 9/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 9/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | BMP1 | P13497 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115224 | 0.90 | PSEN1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1115051 | 0.88 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1115215 | 0.87 | PSEN1 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7990181 | 0.85 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1115232 | 0.85 | PSEN1 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1115024 | 0.84 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7977703 | 0.84 | PSEN1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1115067 | 0.83 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7967715 | 0.83 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1115193 | 0.83 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | BRISTOL- MYERS SQUIBB COMPANY | 2011-03-10 | — | — | US | claimed |
| EP-2278878-A1 | 2-ARYL GLYCINAMIDE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2011-02-02 | — | — | EP | claimed |
| WO-2009137657-A1 | 2-ARYL GLYCINAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-12 | — | — | WO | claimed |
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | BRISTOL- MYERS SQUIBB COMPANY | 2011-03-10 | — | — | US | disclosed |
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | BRISTOL- MYERS SQUIBB COMPANY | 2011-03-10 | — | — | US | disclosed |
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | BRISTOL- MYERS SQUIBB COMPANY | 2011-03-10 | — | — | US | disclosed |
| EP-2278878-A1 | 2-ARYL GLYCINAMIDE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009137657-A1 | 2-ARYL GLYCINAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059940-A1 | 2-Aryl Glycinamide Derivatives | IAPP, APP, BACE1 | PSEN1 8/4885PSEN2 6/4885APH1B 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.